Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types.

ABSTRACT:

Background

PD(L)1 antibodies (anti-PD(L)-1) have been a major breakthrough in several types of cancer. Novel patterns of response and progression have been described with anti-PD(L)-1. We aimed at characterizing pseudoprogression (PSPD) among patients with various solid tumor types treated by anti-PD(L)-1.

Methods

All consecutive patients (pts) enrolled in phase 1 trials with advanced solid tumors and lymphomas treated in phase I clinical trials evaluating monotherapy by anti-PD(L)-1 at Gustave Roussy were analyzed. We aimed to assess prevalence and outcome of PSPD across tumor types. We also intended to describe potential clinical and pathological factors associated with PSPD.

Results

A total of 169 patients treated with anti-PD(L)-1 were included in the study. Most

SUBMITTER: Martin-Romano P 

PROVIDER: S-EPMC7163099 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature